Aurinia Pharmaceuticals has reported positive interim results from the AURORA 2 continuation study of Lupkynis (voclosporin) to treat lupus nephritis (LN).

The structurally modified calcineurin inhibitor (CNI) Lupkynis is intended to treat adult patients with LN, which is a serious manifestation of systemic lupus erythematosus (SLE).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The randomised, double-blind, placebo-controlled Phase III AURORA 2 clinical trial is evaluating the tolerability and safety of the oral medicine to treat LN in patients with SLE, a complex chronic autoimmune disease.

Participants who have completed a one-year treatment during the Phase III AURORA 1 trial were eligible for enrolment in the AURORA 2 continuation study.

In this study, the LN patients were given 23.7mg voclosporin or placebo in combination with 1g mycophenolate mofetil twice a day for 24 additional months.

According to the interim analysis, around 216 patients continued into the AURORA 2 study and received total treatment for 30 months.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It was observed that the patients in the LN group who received Lupkynis sustained meaningful reductions in proteinuria with a stable estimated glomerular filtration rate (eGFR) at 30 months.

Furthermore, lupkynis showed sustained safety and tolerability compared to placebo.

Aurinia Pharmaceuticals chief medical officer Neil Solomons said: “We are encouraged to see the continued positive outcomes with Lupkynis and look forward to seeing and presenting the complete results from AURORA 2 in the coming months.”

The final results of the AURORA 2 continuation study are anticipated to be released by the end of this year.

In May 2021, Aurinia reported positive results from a Phase III AURORA 1 study of oral therapy Lupkynis in adult patients with LN.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact